Integer Holdings Corporation
https://www.integer.net/home/default.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Integer Holdings Corporation
Deal Watch: Roche, PhoreMost Enter Into Multi-Target Collaboration
Plus deals with Synaffix/Emergence, Helsinn/Juniper and Sanyou/Shanghai KangaBio, while Takeda/Finch and Dong-A/Beactica ended prior collaborations.
Dealmaking Quarterly Statistics, Q2 2022
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Finance Watch: Latest Slate Of VC Mega-Deals Led By China-Based Biopharmas
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Company Information
- Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
-
- Aran Biomedical Ltd.
- CCC Medical Devices
- Greatbatch, Inc.
- InoMec Ltd.
- Lake Region Medical Holdings, Inc.
- NeuroNexus Technologies
- Oscor, Inc.
- Quan Emerteq LLC
- US BioDesign, LLC